About Shionogi Inc.
Management Team
John Keller, Ph.D., President and Chief Executive Officer
Dr. Keller joined Shionogi Inc. in July of 2010, as Executive Vice President, Corporate Development and Strategy, and was appointed President and Chief Executive Officer in April 2011.
Immediately prior to joining Shionogi, Dr. Keller was a Partner in SR One, the venture capital group of GlaxoSmithKline, leading spin-out and incubator initiatives. Previously, Dr. Keller served as Executive Vice President and Chief Business Officer of Incyte Corporation, establishing Incyte’s first major corporate alliance after its transformation into a drug discovery and development company, a collaboration with Pfizer valued at over $800 million. Before Incyte, Dr. Keller had a 16 year tenure at GlaxoSmithKline and its predecessor, SmithKline Beecham, culminating in the position of Vice President, Worldwide Business Development. In that role, he structured numerous licensing agreements with a broad range of partners worldwide, including major global pharmaceutical businesses, mid-sized healthcare companies, and emerging and late-stage biotechnology firms. Earlier positions encompassed technology licensing, alliance management, R&D strategy, project management, genomic technology, and discovery research.
Dr. Keller holds a Ph.D. in microbiology from Rutgers University and a Bachelor degree in biology from Johns Hopkins University.